Dr. Sherif joined Oculis from Novartis where he served as Entrepreneur in Residence at Novartis Venture Fund during 2017. Prior to this, he held senior positions in global business development both at Alcon, where he was Region President of Europe, Middle East and Africa, and Novartis Pharmaceuticals, where he served as President of Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles as Head of Transplant and Infectious Disease for Latin America, and Head of the Novartis Vaccines and Diagnostics Division for Latin America.
Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a Specialized Master’s degree in Medical Management.
Dr. Loftsson is a leading scientist in the field of nanoparticle drug delivery, in particular cyclodextrin-based formulations. He has served as an advisor to many of the global pharmaceutical companies on drug formulations and IP rights. Dr. Loftsson co-founded and served as CEO of the biotechnology company Cyclops ehf. from 1994 until it was acquired by DeCode Genetics in 2000. At that time, he also took on the role of scientific advisor at Decode Genetics, until 2004. Dr. Loftsson received an MS degree in Pharmacy from the University of Copenhagen, School of Pharmaceutical Sciences and MS and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas, Department of Pharmaceutical Chemistry. He has served as Assistant, Associated and full Professor on the Faculty of Pharmaceutical Sciences, University of Iceland for over 35 years. Dr. Loftsson has authored and co-authored more than 220 peer-reviewed papers in addition to a couple of books and a number of book chapters. He is a fellow of the AAPS and is on the editorial boards of the Journal of Pharmaceutical Sciences, International Journal of Pharmaceuticals, Journal of Drug Delivery Science and Technology, Die Pharmazie, and the Journal of Pharmacy and Pharmacology. In 2014, Dr. Loftsson was recognized as one of the World’s Most Influential Scientific Minds by Thomson Reuters.
Dr. Pilotaz joins Oculis with more than 20 years’ experience in innovation of global sterile health products in both pharmaceutical and medical device industries, including 15 years in the Ophthalmology sector specifically. Most recently, he was Senior Director and Head of CMC and Pharmaceutical Operations at Nicox S.A. in charge of several outstanding ophthalmic development projects for the USA market. He has previously worked for Becton Dickinson and Laboratoires Thea with multiple incremental leadership positions in the R&D field.
Dr. Pilotaz completed a doctorate degree in pharmacy from the Grenoble school of pharmacy and he has a noteworthy experience in both intellectual property, project management, device design and marketing. He has an extensive track record in sterile drug design, development, industrialization and registration. He is co-author in 5 formulation patents for topical ophthalmic drugs and successfully contributed to multiple drugs commercialized in both Europe and USA.